Osaka trial: A randomized, controlled trial comparing tacrolimus qd and bd in kidney transplantation

Transplantation

Volumn 96, Issue 10, 2013, Pages 897-903

  Albano, Laetitia ^a   Banas, Bernhard ^b   Klempnauer, Juergen L ^c   Glyda, Maciej ^d   Viklicky, Ondrej ^e   Kamar, Nassim ^f,g  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d District Hospital   (Poland)

^e INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g CHU RANGUEIL   (France)

Author keywords

Composite endpoint for graft failure.; Extended criteria donor; Kidney transplantation; Tacrolimus

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMOCYSTOSIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL;

ADULT; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TREATMENT OUTCOME;

EID: 84891836124     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182a203bd     Document Type: Article

References (21)

1. European Medicines Agency. Committee for Medicinal Products for Human Use (2012). CHMP PharmacokineticsWorking Party (PKWP). Questions and answers: positions on specific questions addressed to the Pharmacokinetics Working Party. London. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002963.pdf. Accessed May 2012.
2. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007; 2: 374.
3. Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients. Transplantation 2011; 92: 648.
4. Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757.
5. Stevenson KS, Glen J, Stevens KK, et al. High tacrolimus intrapatient variability is associated with acute rejection and graft loss (abstract MO-021). Transpl Int 2011(Suppl 2); 24: 111.
6. Guirado L, Cantarell C, Franco A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant 2011; 11: 1965.
7. Morales JM, Varo E, La'zaro P. Immunosuppressant treatment adherence, barriers to adherence and quality of life in renal and liver transplant recipients in Spain. Clin Transplant 2012; 26: 369.
8. Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronicmonitoring. Transplantation 2013; 95: 333.
9. Beckebaum S, Jacob S, Sweid D, et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int 2011; 24: 666.
10. Wlodarczyk Z, Squifflet JP, OstrowskiM, et al. Pharmacokinetics for onceversus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009; 9: 2505.
11. European Medicines Agency. Committee for Medicinal Products for Human Use (2008). Guideline on Clinical Investigation of Immunosuppressants for Solid Organ Transplantation. London. http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003593.pdf. Accessed May 2012.
12. Silva HT Jr, Yang HC, Abouljoud M, et al.One-year results with extendedrelease tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595.
13. Krämer BK, Charpentier B, Bäckman L, et al. for the Tacrolimus Prolonged Release Renal Study Group. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010; 10: 2632.
14. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
15. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
16. De Greef KE, Ysebaert DK, Vercauteren SR, et al. Effect of immunosuppression on damage, leukocyte infiltration, and regeneration after severe warm ischemia/reperfusion renal injury. Transplant Proc 2002; 34: 791.
17. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
18. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807.
19. Vítko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimensVtacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetilVin comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005; 80: 1734.
20. Vítko S, Wlodarczyk Z, Kyllo?nen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 2006; 6: 531.
21. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2002; 2: 701.